These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7384201)

  • 1. Effect of gamma radiation on the molecular weight and the anticoagulant activity of heparin.
    Chawla AS; Hayward C
    Pharmacology; 1980; 20(4):224-8. PubMed ID: 7384201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of heparin into fractions with different anticoagulant activity by hydrophobic interaction chromatography.
    Ogamo A; Uchiyama H; Nagasawa K
    Biochim Biophys Acta; 1980 Dec; 626(2):477-85. PubMed ID: 7213665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity.
    Lopalco L; Ciccomascolo F; Lanza P; Zoppetti G; Caramazza I; Leoni F; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):787-93. PubMed ID: 7986584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. I. Effects of heparin fractions.
    Schmitz-Huebner U; Balleisen L; Asbeck F; van de Loo J
    Thromb Haemost; 1981 Oct; 46(3):612-6. PubMed ID: 7031982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular weight determination of commercial heparin sodium USP and its sterile solutions.
    Rodriguez HJ; Vanderwielen AJ
    J Pharm Sci; 1979 May; 68(5):588-91. PubMed ID: 571022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on a highly active anticoagulant fraction of high molecular weight isolated from porcine sodium heparin.
    Sache E; Maillard M; Bertrand H; Maman M; Kunz M; Choay J; Fareed J; Messmore H
    Thromb Res; 1982 Mar; 25(6):443-58. PubMed ID: 7112506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sulfation and Molecular Weight on Anticoagulant Activity of Dextran.
    Drozd NN; Logvinova YS; Torlopov MA; Udoratina EV
    Bull Exp Biol Med; 2017 Feb; 162(4):462-465. PubMed ID: 28243911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The uronic acid composition of anticoagulantly active and inactive heparin.
    Rosenfeld L; Radoff S; Danishefsky I
    Arch Biochem Biophys; 1985 Nov; 242(2):574-8. PubMed ID: 4062296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High and low anticoagulant activity heparins. Preparation in large scale and degree of complexation with antithrombin III.
    Takahashi HK; Nader HB; Dietrich CP
    Arzneimittelforschung; 1985; 35(11):1620-3. PubMed ID: 4091864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
    Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
    Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of heparin and heparin fractions on platelet aggregation.
    Salzman EW; Rosenberg RD; Smith MH; Lindon JN; Favreau L
    J Clin Invest; 1980 Jan; 65(1):64-73. PubMed ID: 6243142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of crude heparin and commercial preparation of Polish production].
    Jarzebiński J; Tońska S; Remiszewska H
    Acta Pol Pharm; 1989; 46(2):179-82. PubMed ID: 2561044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low anticoagulant heparin retains anti-HIV type 1 activity in vitro.
    Coombe DR; Harrop HA; Watton J; Mulloy B; Barrowcliffe TW; Rider CC
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1393-6. PubMed ID: 8573397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The new heparins].
    Samama M
    Presse Med; 1986 Sep; 15(32):1631-5. PubMed ID: 2949211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low molecular weight heparin on coagulation parameters and bleeding time in healthy volunteers.
    Warning A; Nies D; Wolf H; Welzel D
    Arzneimittelforschung; 1987 Jul; 37(7):847-9. PubMed ID: 2823841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.